|
|
- For other uses, see Élan (disambiguation).Template:Infobox Company
Élan Corporation plc Template:Nyse, Template:Lse is a major drugs firm based in Athlone, County Westmeath, Ireland. In the late 1990's its value as a PLC on the ISEQ Stock Exchange reached over €20bn. It was one of Ireland's major business success stories. However in the early years of 2000's an accounting scandal and investor reactions to the global slump, caused a major devaluation resulting in a share price slump of over 90%. Since then the company has regained its growth path under the reign of a new American CEO Kelly Martin.
Today, Élan still employs over 2,000 people in Ireland. It is listed on the New York Stock Exchange as ELN, the Dublin Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L.
Élan is currently focusing its research on a ground-breaking drug for Alzheimer's disease.
On 28th February 2005, Élan announced that it was withdrawing its Tysabri drug, after reports that a patient died after usage. This has led to its share price dropping by 70%.
See Also
External links
- Information about Élan (http://www.bioscorpio.com/elan_corp_plc.htm)
- Wikinews report of Tysabri withdrawal (http://en.wikinews.org/wiki/Elan%3B_Biogen_withdraw_MS_drug_after_death)
- Élan stock on the Irish Stock Exchange (http://www.ise.ie/app/equityDetails.asp?equity=530)